Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
Funda Meric-BernstamVicky MakkerAna OakninDo Youn OhSusana BanerjeeAntonio Gonzáles MartinKyung Hae JungIwona ŁugowskaLuis Manso SanchezAránzazu ManzanoBohuslav MelicharSalvatore SienaDaniil StroyakovskiyAnitra FieldingYan MaSoham PuvvadaNorah ShireJung-Yun LeePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Our study demonstrates durable clinical benefit, meaningful survival outcomes, and safety consistent with the known profile (including ILD) in pre-treated patients with HER2-expressing tumors receiving T-DXd. Greatest benefit was observed for the IHC 3+ population. These data support the potential role of T-DXd as a tumor-agnostic therapy for patients with HER2-expressing solid tumors.